WNT5A and myeloid sarcoma: A role for aberrant Wnt (wingless-type protein-1) signalling in the pathogenesis of MS-associated neuropathic pain is supported by observations of upregulated expression of the Wnt ligands, Wnt3a, Wnt5a and their downstream effector, β-catenin in the spinal dorsal horn in EAE-mice, with pain behaviours attenuated by treatment with the Wnt5a antagonist, Box5, or the β-catenin inhibitor, indomethacin (Yuan et al. 2012).